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Abstract
The tumor suppressor Rb is a nuclear phosphoprotein that controls cell growth and differentiation by modulating the
activity of certain transcription factors. Transport of Rb to the nucleus is affected by both a bipartite nuclear localization
signal (NLS) in the C-terminus of the protein and a central domain, termed A/B or pocket, through which Rb interacts with
transcription factors and viral oncoproteins. Mutations in either the A or B subdomains of the pocket render a NLS-deficient
Rb completely cytoplasmic. Fusing the A/B domain of Rb to the Escherichia coli L-galactosidase, to create Lgal-A/B, confers
nuclear localization upon this bacterial protein. Moreover, co-expression with the adenovirus oncoprotein, E1A, further
augments nuclear localization of Lgal-A/B. These findings provide direct evidence that the pocket domain of Rb is not only
required but also sufficient to induce nuclear transport by a ‘piggyback’ mechanism. Thus, nuclear localization of Rb is
dictated by two independent and autonomous domains: (i) the bipartite NLS and (ii) the pocket domain. We suggest that via
these domains, Rb chaperons and co-compartmentalizes with its associated factors and preempts their activity prior to
nuclear transport. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The tumor suppressor Rb controls the G1/S tran-
sition by modulating the activity of transcriptional
factors such as E2F1 [1]. In addition, Rb interacts
with di¡erentiation factors such as MyoD and
C/EBP and facilitates di¡erentiation of muscles, adi-
pocytes and other tissues in vitro [2,3]. Analysis of
Rb-de¢cient mice revealed that Rb is required for
permanent withdrawal of cells from a proliferating
phase and the onset and maintenance of terminal
di¡erentiation (reviewed in [4]). The activity of Rb
is tightly regulated by cyclin-dependent kinases
(CDKs). Components of the CDK4-cyclin D1 com-
plex, the CDK inhibitor p16 and Rb itself constitute
a pathway that is often disrupted in human cancer.
Dysregulation of the Rb pathway occurs either by
activation of CDK4 or cyclin D1, or by inactivation
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of p16 or Rb (reviewed in [5]). Restoration of the Rb
pathway either by targeting the CDKs or by recon-
stitution with Rb results in suppression of cell
growth of both normal and tumor cells (see [6] and
references therein).
The observation that the Rb pathway is inacti-
vated in virtually all human cancer raises the pros-
pect that restoration of this pathway to human tu-
mors may be a viable approach to reduce neoplastic
growth. The delivery of Rb into tumor cells might be
facilitated by the observation that upon addition of
recombinant Rb to cells in culture, the protein is
readily taken up by cells, translocated to the nucleus
and suppresses cell growth [7]. In the nucleus, Rb co-
localizes with the nuclear matrix [8] at the hetero-
chromatin-euchromatin border [9]. In herpesvirus-in-
fected cells, Rb co-localizes with p53 and host repli-
cation proteins at sites of viral DNA replication [10].
Biochemical analysis reveals that hypo-phospho-
rylated active Rb is tightly tethered in the nucleus
whereas hyperphosphorylated or mutant species
readily leak out under low ionic conditions [11]. In
addition, puri¢ed Rb promptly reassociates with
nuclei in vitro [12]. All these observations indicate
that the subcellular localization of Rb is under an
active control and that understanding the underlying
mechanisms may be instrumental in developing Rb
alleles with superior nuclear translocation compe-
tence.
As a ¢rst step towards understanding the mecha-
nisms governing the transport of Rb to the nucleus,
we have previously identi¢ed a bipartite nuclear lo-
calization motif at the C-terminus of Rb [13]. Abro-
gation of this nuclear localization signal (NLS)
yielded a protein, RbvNLS, that is distributed in
some transfected cells both in the nucleus and cyto-
plasm and in other cells predominantly in the cyto-
plasm. Complete cytoplasmic localization was
achieved only when in addition to the NLS, the
pocket (A/B) domain of Rb required for protein-pro-
tein interaction was also disrupted [13]. These obser-
vations suggest that RbvNLS may be transported to
the nucleus via the pocket domain by a ‘piggyback’
mechanism. In the present study, we have directly
tested this conjecture by transiently expressing the
pocket domain of Rb fused to an otherwise cytoplas-
mic protein, Escherichia coli L-galactosidase, and
shown that the pocket domain, either alone or to-
gether with the adenovirus oncoprotein E1A, can
actively localize to the nucleus and confer nuclear
localization upon a heterologous protein.
2. Materials and methods
2.1. Cell culture and transfection
The RB-mutant cervical carcinoma C33A and os-
teosarcoma Saos-2 cell lines (obtained from the
American Culture Collection) and NIH3T3 mouse
¢broblasts were cultured in KMEM medium (Gib-
co-BRL), supplemented with 10% fetal calf serum.
Plasmid DNAs were puri¢ed on Qiagen columns.
Cells were plated in 60 mm dishes and transfected
by the calcium phosphate method the following day
at about 50% con£uence. For immunostaining, cov-
erslips were sterilized by immersing in 75% ethanol
and placed in 60 mm dishes prior to plating. Cells
were washed once with PBS 6^8 h after transfection,
re-incubated in the same medium (KMEM plus 10%
FCS) and assayed 2 days later.
2.2. Plasmids
All plasmids were prepared in pECE backbone
under the control of the SV40 early promoter and
polyadenylation signal. The 3P end of pECE-Lgal was
modi¢ed with a linker containing the following sites:
EcoRI-EagI-SmaI-XhoI-stop-stop-XbaI (pECE-Lgal
{L}, the two stop codons are on di¡erent frames).
Wild type RB1 plasmid was puri¢ed from a dam3/
dcm3 bacterial strain and digested with AsnI located
just upstream of the A domain, blunt ended and cut
with StuI located just downstream of the B domain.
The A/B-containing fragment (aa 379^768) was
subcloned in frame into a SmaI-linearized pECE-
Lgal {L}, yielding Lgal-A/B. vDra and v22 deriva-
tives were constructed as described [13,14]. LGal-B
was constructed by cutting Lgal-A/B with EagI and
PstI (partial digest), which releases the A domain,
and replacement with a double-stranded EagI-PstI
linker (5P-GTATGGTTACC). The vNBA allele
was created by inserting a linker between AsnI in
exon 10 (just upstream of the A subdomain) and a
BstEII site in the spacer region separating the A and
B subdomains.
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2.3. Immunostaining
Immunostaining using horseradish peroxidase
(HRP)-conjugated or £uorescent secondary antibod-
ies were performed as described in [13] and [14], re-
spectively. The monoclonal anti-Rb (G3-245) was
obtained from PharMingen. Polyclonal rabbit anti-
L-galactosidase was purchased from 5P to 3P Inc. The
monoclonal antibody to adenovirus 2 E1A (AB-1)
was from Oncogene Science. HRP-conjugated goat
anti-mouse and anti-rabbit secondary antibodies
were from Bio-Rad. Rhodamine-conjugated goat
anti-rabbit and £uorescein (FITC)-conjugated goat
anti-mouse were purchased from Jackson Immuno-
research Laboratories Inc.
2.4. Immunoblots
Nuclear-cytoplasmic fractionation was performed
as described [15] except that (i) the hypotonic
bu¡er (10 mM Tris pH 7.6/10 mM KCl/2 mM
MgCl2 plus proteinase inhibitors) included 0.1%
Triton X-100 and (ii) instead of using Dounce
homogenizer, the swollen cells were disrupted by
20 rapid passages through a Pasteur pipette. The ex-
tent of cellular disruption and the appearance of iso-
lated nuclei were monitored microscopically. For co-
immunoprecipitation of Lgal-A/B and E1A, C33A
cells were transfected with Lgal-A/B or Lgal-A/
BvDra (9 Wg) with or without genomic E1A (1 Wg).
Two days later, the cells were washed three times
with cold PBS and lysed in 1 ml lysis bu¡er
(50 mM Tris-HCl pH 7.5, 0.5% NP-40, 120 mM
NaCl supplemented with proteinase inhibitors
PMSF, aprotinin and leupeptin). Portions of 50 Wl
were used for Western blotting. For co-immunopre-
cipitation, lysates (1 ml) were ¢rst immunoreacted
with monoclonal anti-E1A by rocking for 60 min
at 4‡C, and precipitated for an additional 40 min
with agarose-conjugated anti-mouse antibodies (Sig-
ma), that had been prewashed four times in lysis
bu¡er. Immunoprecipitates were washed four times
in lysis bu¡er containing 1 mM EDTA and then
analyzed by Western blotting, using rabbit polyclo-
nal anti-L-galactosidase (1:500) and monoclonal anti
E1A (1:1000). Western blots were developed using
an ECL kit (Amersham).
3. Results
3.1. Partial nuclear localization of RbvNLS
We have previously shown by immunostaining of
transiently transfected cells that a mutant Rb allele,
RbvNLS, in which a bipartite NLS in exon 25 is de-
leted, is distributed in some transfected cells predom-
inantly in the cytoplasm and in other cells in both
the nuclear and cytoplasmic compartments [13]. We
have now used sub-cellular fractionation and West-
ern blotting to further demonstrate the partial nu-
clear localization of RbvNLS. RB-mutant cervical car-
cinoma C33A cells were transfected with plasmids
expressing wild-type and mutant alleles of Rb, lysed
in hypotonic bu¡er, fractionated into nuclear pellets
and soluble supernatants and Western blotted with
anti-Rb antibodies (Fig. 1). As previously demon-
strated [11,15], hyperphosphorylated and mutant
Rb alleles leak out of the nucleus under hypotonic
conditions, while underphosphorylated Rb species
remain tethered in the nucleus (Fig. 1). Under these
Fig. 1. Partial nuclear localization of RbvNLS. C33A cells were
transfected with plasmids expressing Rbwt, Rbv22 or RbvNLS.
Cells were fractionated under low salt condition into a nuclear
pellet (P) and a soluble supernatant (S), separated on SDS-
PAGE gel and immunoblotted with anti-Rb antibody. The po-
sitions of phosphorylated (ppRb) and unphosphorylated (pRb)
species of Rb are shown.
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hypotonic conditions, RbvNLS was found in the pellet
and supernatant just like wild-type Rb (Fig. 1). In-
deed, by subcellular fractionation, there was little
di¡erence between Rb and RbvNLS ; the partial cyto-
plasmic distribution of the latter is only revealed by
immunostaining ([13] and data not shown). In con-
trast, Rbv22, with a deletion that disrupts the pocket
domain, was recovered exclusively in the soluble
fraction (Fig. 1). These results con¢rm our previous
¢ndings that an Rb allele, RbvNLS, devoid of a nu-
clear localization signal is still capable of partial nu-
clear localization.
3.2. Nuclear localization of RbvNLS is completely
disrupted by independent mutations in the A and
B subdomains
The A and B subdomains of Rb can act independ-
ently in some experimental assays. For example, the
interaction of Rb with MyoD in vitro involves only
the B subdomain [2]. We have previously shown that
a deletion of exon 22 in the B domain of Rb plus
disruption of the NLS, pRbNLSv22, were both re-
quired to abrogate nuclear transport of Rb [13].
We have now extended this analysis to test whether
Fig. 2. Both A and B subdomains of the pocket are required for partial nuclear localization of RbNLS. A schematic presentation of
Rb alleles and a summary of their subcellular localization. The various Rb alleles were created as described in Section 2, transfected
into Saos-2 cells and subcellular localization was determined by immunostaining with anti-Rb antibody.
Fig. 3. The A/B domain of Rb confers nuclear localization upon heterologous protein. Schematic structure of Lgal-A/B plasmids used
in this study and summary of the subcellular distribution of the corresponding proteins in Saos-2, C33A and NIH3T3 cells as shown
in Figs. 5 and 6.
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independent mutations in the A and B subdomains
have similar e¡ects on nuclear transport. Two addi-
tional alleles were created: pRbNLSvDra contains a
two amino acid deletion in exon 20 in the B subdo-
main and pRbNLSvNBA has a deletion of the entire A
domain (Fig. 2). Like pRbNLSv22, both pRbNLSvDra
and pRbNLSvNBA were found exclusively in the cyto-
plasm of transfected cells (Fig. 2, data not shown).
These results indicate that the integrity of the entire
pocket domain is required for the partial nuclear
localization RbvNLS.
3.3. The pocket domain is biologically active and
confers nuclear localization when fused to a
heterologous cytoplasmic protein
To directly determine whether the pocket domain
is not only required but also su⁄cient to induce nu-
Fig. 4. Co-immunoprecipitation of Lgal-A/B but not Lgal-A/
BvDRA with adenovirus E1A. C33A cells were transfected with
Lgal-A/B or Lgal-A/BvDRA (9 Wg) either alone (Straight West-
ern) or together with E1A (1 Wg). For straight Western, frac-
tions of 50 Wl/ml of the lysates were fractionated on 7.5% SDS-
PAGE gels directly. For co-immunoprecipitation, whole lysates
(1 ml) were ¢rst immunoprecipitated with anti-E1A antibody.
The blot was developed with anti-L-galactosidase polyclonal
antibody (top) or anti-E1A monoclonal antibody (bottom).
Fig. 5. Subcellular localization of Lgal, Lgal-A/B and Lgal-A/BvDRA fusion proteins in transfected C33A and NIH3T3 cells. Note that
Lgal and Lgal-A/BvDRA are invariably cytoplasmic whereas Lgal-A/B is both nuclear and cytoplasmic in C33A cells and predominantly
nuclear in NIH3T3 cells.
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clear localization, we fused the pocket (aa 379^768)
to the C-terminus of the E. coli L-galactosidase,
which normally localizes in the cytoplasm (yielding
Lgal-A/B) (Fig. 3). To control for speci¢city, several
mutant A/B domains, v22, vDra (B domain muta-
tions) or the B domain alone were fused to the L-
galactosidase gene to yield Lgal-A/Bv22, Lgal-A/BvDra
and Lgal-B, respectively.
We ¢rst tested whether the A/B domain in the
Lgal-A/B fusion protein retained biological activity.
Plasmids expressing Lgal-A/B or Lgal-A/BvDra were
transfected into C33A cells either alone or together
with E1A and cell lysates were fractionated directly
on SDS-PAGE gels or ¢rst immunoprecipitated with
antibodies to E1A. Blots were immunoreacted with
anti-L-galactosidase antibodies. As shown in Fig. 4,
Lgal-A/B co-immunoprecipitated with E1A, whereas
Lgal-A/BvDra did not, indicating that the A/B domain
of Rb can function autonomously and bind E1A
when fused to L-galactosidase.
We then examined the subcellular localization of
Lgal-A/B and mutant derivatives in three cell lines:
two Rb-mutant human lines, C33A and Saos-2, and
the RB-wild-type mouse cell line, NIH3T3. The pa-
rental Lgal and the Lgal-A/Bv22, Lgal-A/BvDra and
Lgal-B mutants were exclusively cytoplasmic in all
three cell lines (Fig. 5, A^C, G-I; Fig. 6A, A,B and
data not shown). In contrast, Lgal-A/B was more
nuclear than cytoplasmic in NIH3T3 (Fig. 5, E,F)
and Saos-2 cells (Fig. 6A, C,E) while in C33A cells
it was in di¡erent transfected cells either predomi-
nantly nuclear, both nuclear and cytoplasmic or pre-
dominantly cytoplasmic (Figs. 5, D, 6B, B). The ba-
sis for these small variations in the distribution of
Lgal-A/B in di¡erent cell lines is unknown. However,
the results clearly demonstrate that the A/B domain
can induce partial nuclear localization when fused to
a heterologous protein.
3.4. Co-translocation of Lgal-A/B but not Lgal-A/
BvDra with E1A
If the pocket (A/B) domain induces nuclear local-
ization by a ‘piggyback’ mechanism, Lgal-A/B should
localize more e⁄ciently in the nucleus in the presence
of a Rb-binding nuclear factor. To test this hypoth-
esis, plasmids expressing Lgal-A/B or Lgal-A/BvDra
were transfected either alone or with E1A. While
Lgal-A/B co-localized to both cytoplasm and nucleus
of Saos-2 cells, co-transfection with E1A resulted in
complete nuclear localization (Fig. 6A, C^F), where-
as Lgal-A/BvDra was refractory to the presence of
E1A (Fig. 6A, A,B).
To further demonstrate the e¡ect of E1A on the
subcellular localization of Lgal-A/B we used double
£uorescent immunostaining of co-transfected C33A
cells. When transfected alone, Lgal-A/B was variably
in the cytoplasm, throughout the cell or in the nu-
cleus, whereas Lgal-A/BvDra was uniformly cytoplas-
mic (Fig. 6B, A,B). When co-transfected with E1A,
Lgal-A/B co-localized with E1A exclusively in the
nucleus of C33A cells (Fig. 6B, C,D). In contrast,
Lgal-A/BvDra remained cytoplasmic even in the pres-
ence of nuclear E1A (Fig. 6B, E,F). We conclude
that the pocket domain of Rb can confer nuclear
localization upon a heterologous protein by a ‘piggy-
back’ mechanism, whereby Rb binds nuclear factors
such as E1A and co-translocates to the nucleus.
4. Discussion
In this report, we show that the pocket domain of
Rb is not only required but also su⁄cient for nuclear
transport. We have shown that fusion of the A/B
domain to the L-galactosidase gene induces nuclear
localization and that this nuclear tethering is dis-
rupted by mutations in the A/B domain and en-
hanced by co-transfection with E1A. We have previ-
ously found that cytoplasmic alleles of Rb can
sequester E2F1 in the cytoplasm in co-transfection
experiments, suggesting that Rb and E2F1 may nor-
mally co-translocate into the nucleus as a complex
driven by the NLS of Rb [14]. Thus, the nuclear
factor(s) responsible for the partial nuclear localiza-
tion of RbvNLS and Lgal-A/B are likely distinct from
E2F1 and remain to be identi¢ed. We have also
shown previously that the biological activity of a
NLS-de¢cient Rb allele was reduced but not abol-
ished [13]. Thus, despite the fact that the pocket do-
main can confer nuclear localization, this ‘piggyback’
mechanism is not su⁄cient and an intact NLS is
critical for full biological activity of this tumor sup-
pressor protein. The observed ‘piggyback’ transport
of the Rb pocket supports a model in which Rb co-
translocates to the nucleus in association with cellu-
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lar factors. This co-transport mechanism may allow
Rb to chaperon its associated proteins from the cy-
toplasm to the nucleus resulting in co-compartmen-
talization and preemptive transcriptional repression
during the G1 phase of the cell cycle.
The A/B domain is composed of two non-contig-
uous subdomains (A and B) frequently disrupted by
mutations in human cancer [16]. These mutations
disrupt binding to transcription and di¡erentiation
factors such as E2F and MyoD and abrogate bio-
logical activity. The A and B subdomains are some-
what homologous to the TATA-binding factor TBP
Fig. 6. Co-translocation of Lgal-A/B but not Lgal-A/BvDRA with E1A in Saos-2 cells. (A) Saos-2 cells were transfected with Lgal-A/
BvDRA (A) or Lgal-A/B (C,E) alone or together with E1A (B,D,F) and immunostained with anti-L-galactosidase antibody. Note com-
plete nuclear localization of Lgal-A/B in the presence of E1A. (B) Co-translocation of Lgal-A/B but not Lgal-A/BvDRA with E1A in
C33A-2 cells. C33A cells were transfected with Lgal-A/BvDRA (A) or Lgal-A/B (B) either alone or together with E1A (C^F). Trans-
fected cells were immunostained with £uorescent antibodies to L-galactosidase (rhodamine-conjugated ^ red) or E1A (FITC-conjugated
^ green) as described in Section 2. One cell indicated by a yellow arrowhead in panels C and D expressed only Lgal-A/B and showed
predominantly cytoplasmic staining. Note that Lgal-A/B co-localized with E1A in the nucleus (white arrowheads in C and D). In con-
trast Lgal-A/BvDRA (E,F) is cytoplasmic even in the presence of E1A.
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and the basal transcription factor TRIIB, respec-
tively [17]. When fused to the DNA binding domain
of GAL4, the A/B domain represses transcription
[18]. Our results point to an additional function of
the pocket domain: co-transport with other proteins
into the nucleus and nuclear tethering.
We note that Lgal-A/B localizes in the nucleus
more e⁄ciently than RbvNLS. While the subcellular
distribution of RbvNLS was more cytoplasmic than
nuclear, Lgal-A/B was mostly nuclear in NIH3T3
and Saos-2 cells (this study and [13]). One possible
explanation for these di¡erences is that nuclear local-
ization is negatively regulated by phosphorylation of
RbvNLS. Since most of the phosphorylation sites in
Rb are outside the A/B domain, Lgal-A/B is resistant
to phosphorylation and remains invariably active
and tethered in the nucleus.
It was reported that the addition of puri¢ed Rb to
cells in culture results in spontaneous uptake by cells
and subsequently nuclear localization and growth
suppression [7]. Protein sequences that can confer
nuclear transport from outside the cells have been
identi¢ed ([19,20] and references therein). We have
shown that nuclear localization of Rb is dictated
by two independent and autonomous domains: (i)
a bipartite NLS and (ii) the pocket domain. Whether
any of these domains in Rb can mediate the trans-
port of Rb from outside the cell is yet to be deter-
mined. Dimerization of these sequences coupled with
mutations in phosphorylation sites in Rb may en-
hance cellular/nuclear targeting and resistance to
CDKs, yielding superior Rb alleles suitable for solu-
ble Rb-based protein therapy.
Acknowledgements
This work was supported by grants from the
Canadian Breast Cancer Research Initiative; Medi-
cal Research Council of Canada and Canadian
Breast Cancer Foundation for E.Z. and the National
Cancer Institute of Canada with funds from the
Terry Fox Run; the Medical Research Council of
Canada and the Retinoblastoma Family Association
and the Royal Arch Masons of Canada for R.A.P.
and B.L.G.
References
[1] J.R. Nevins, G. Leone, J. DeGregori, L. Jakoi, J. Cell Phys-
iol. 173 (1997) 233^236.
[2] W. Gu, J.W. Schneider, G. Condorelli, S. Kaushal, V. Mah-
davi, B. Nadal-Ginard, Cell 72 (1993) 309^324.
[3] P.L. Chen, D.J. Riley, Y. Chen, W.-H. Lee, Genes Dev. 10
(1996) 2794^2804.
[4] G. Mulligan, T. Jacks, Trends Genet. 14 (1998) 223^229.
[5] R.A. Weinberg, Cell 81 (1995) 323^330.
[6] D.J. Riley, A.Y. Nikitin, W.H. Lee, Nature Med. 2 (1996)
1316^1321.
[7] D. Antelman, T. Machemer, B.G. Huyghe, H.M. Shepard,
D. Maneval, D.E. Johnson, Oncogene 16 (1995) 697^
704.
Fig. 6 (continued).
BBAMCR 14529 3-9-99 Cyaan Magenta Geel Zwart
E. Zacksenhaus et al. / Biochimica et Biophysica Acta 1451 (1999) 288^296 295
[8] M.A. Mancini, B. Shan, J.A. Nickerson, S. Penman, W.H.
Lee, Proc. Natl. Acad. Sci. USA 91 (1994) 418^422.
[9] L. Szekely, E. Uzvolgyi, W.Q. Jiang, M. Durko, K.G. Wi-
man, G. Klein, J. Sumegi, Cell Growth Di¡er. 2 (1991) 287^
295.
[10] D. Wilcock, D.P. Lane, Nature 349 (1991) 429^431.
[11] S. Mittnacht, R.A. Weinberg, Cell 65 (1991) 381^393.
[12] D.J. Templeton, Mol. Cell. Biol. 12 (1992) 435^443.
[13] E. Zacksenhaus, R. Bremner, R.A. Phillips, B.L. Gallie,
Mol. Cell. Biol. 13 (1993) 4588^4599.
[14] E. Zacksenhaus, Z. Jiang, R.A. Phillips, B.L. Gallie, EMBO
J. 15 (1996) 5917^5927.
[15] D.J. Templeton, S.H. Park, L. Lanier, R.A. Weinberg, Proc.
Natl. Acad. Sci. USA 88 (1991) 3033^3037.
[16] Q.J. Hu, N. Dyson, E. Harlow, EMBO J. 9 (1990) 1147^
1155.
[17] C. Hagemeier, A.J. Bannister, A. Cook, T. Kouzarides,
Proc. Natl. Acad. Sci. USA 90 (1993) 1580^1584.
[18] R. Bremner, B.L. Cohen, M. Sopta, P.A. Hamel, C.J. Ingles,
B.L. Gallie, R.A. Phillips, Mol. Cell. Biol. 15 (1995) 3256^
3265.
[19] R. Fahraeus, J.M. Paramio, K.L. Ball, S. Lain, D.P. Lane,
Curr. Biol. 6 (1966) 84^91.
[20] K.L. Ball, S. Lain, R. Fahraeus, C. Smythe, D.P. Lane,
Curr. Biol. 7 (1997) 71^80.
BBAMCR 14529 3-9-99 Cyaan Magenta Geel Zwart
E. Zacksenhaus et al. / Biochimica et Biophysica Acta 1451 (1999) 288^296296
